The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | The next steps for TGR-1202 and targeting the gene c-Myc
Owen A O’Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, discusses the next steps for studying TGR-1202, which is a novel, next generation PI3K-delta inhibitor with promising activity in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). He also talks about findings concerning the targeting of oncogenes such as c-Myc in aggressive lymphomas, particularly diffuse large B-cell lymphoma (DLBCL).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
